Mitra Biotech accelerates personalized cancer treatment through its proprietary CANscript™ technology, which allows functional analysis of patient-derived cancer tissues to predict therapeutic response. Headquartered in Bangalore, Mitra partners with oncologists and research institutions worldwide to identify the best treatments for individual patients, improving outcomes and minimizing unnecessary side effects.
Their translational research platform bridges the gap between laboratory research and clinical oncology, helping drug developers and clinicians validate therapies more efficiently. The company’s mission centers on advancing precision medicine in cancer care through robust data and patient-centric innovation.
Key Technologies & Services:
-
CANscript™ platform for functional tumor profiling
-
Personalized treatment selection and drug response prediction
-
Translational research for oncology drug development
-
Global collaborations in clinical research
